It likely will surprise no one that we have a slightly different view of the recent round of earnings. Since Lilly began the recent round lets start with our friends In Indianapolis. While everyone is focusing on the continued pricing pressure in the diabetes drug sector, the further commodization of the insulin market and possible changes to Medicare reimbursement i.e. elimination of rebates, this is really old news. The reality is pricing pressure will not go away, insulin has been a commodity for some time and changes to Medicare reimbursement are almost a certainty with drug prices being a . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.